Clinical trialPhase 4Not yet recruiting
Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer
Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study on the Efficacy and Safety of Huaier Granules Combined With Capecitabine Versus Capecitabine Alone in the Treatment of Unresectable Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- Phase 4
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- May 2024
- Expected end
- August 2028
- Enrollment
- 488 participants
- Sites
- 0
- Primary outcomes
- Overall survival
- Sponsor
- Other
- Results posted
- No
- Last update
- 29 April 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a prospective, multicenter, randomized, open, parallel controlled clinical study to evaluate the efficacy and safety of Huaier Granules combined with capecitabine in the treatment of unresectable pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
This study is a prospective, multicenter, randomized, open label, parallel controlled clinical study. It is expected to include approximately 488 patients diagnosed with unresectable pancreatic adenocarcinoma by tissue or cellular pathology who visited the selected research center from April 2024 to March 2026. The treatment regimen will be capecitabine monotherapy orally. Among them, the Huaier group uses "capecitabine+Huaier granules", and is expected to include 244 cases; The control group received capecitabine and is expected to include 244 cases.